In a recent press release, Biogen Idec reported that their oral MS disease-modifier, BG-12, significantly reduced the number of people with MS who had relapses during a two-year study of more than 1,200 people with MS.
Phase 3 Study of Oral BG-12
Laquinimod
At the annual meeting of the American Academy of Neurology in April, Teva Pharmaceuticals reported that their oral MS therapy, Laquinimod, reduced the relapse rate in those taking the drug in a study of 1,106 people with MS.
Both companies are awaiting the results of other phase III trials involving these therapies before submitting applications to the FDA.
.
***************************************************************************************
Help STUART to Educate: Please donate
- all contributions are tax deductible -
.
"Providing You with 'MS Views and News', is what we do"
***************************************************************************************
.
Disclaimer: 'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
0 comments:
Post a Comment